{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T04:16:34Z","timestamp":1787026594236,"version":"build-2736575974"},"reference-count":47,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,9,22]],"date-time":"2023-09-22T00:00:00Z","timestamp":1695340800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>To report a case series of herpetic uveitis following COVID-19 vaccinations.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Demographic, clinical and treatment-related data of herpetic anterior uveitis cases was collected at five tertiary eye hospitals between January 2021 and June 2022. A retrospective database review at one of the centers comparing the number of cases of herpetic eye disease before and after the introduction of COVID-19 vaccination was performed as well.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Twenty-four patients (9 female, 15 male) with a mean age of 54\u2009years (range 28\u201383\u2009years) were diagnosed with herpetic uveitis, reporting an onset of symptoms 3\u201342\u2009days after the first, second or third dose of COVID-19 vaccination. Median time between vaccination and onset of herpetic eye disease was 10\u2009days (mean 12.7\u2009\u00b1\u200910.15\u2009days) days. The administered vaccines were BNT162b2, mRNA-1273, BBIBP-CorV and Ad26.COV2.S. The cases included 11 HSV, 10 VZV and 1 CMV anterior uveitis, 2 were not further specified. There was an equal number of first episodes (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200912, 50%) and recurrent episodes (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200912, 50%). Response to established regimens was generally good. The retrospective database review revealed the exact same incidence of herpetic uveitis during the pandemic and ongoing vaccination compared to prior SARS-CoV-2.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This report includes 24 cases of herpetic anterior uveitis in a temporal relationship to various COVID-19 vaccines. This study supports the potential risk of herpetic eye disease following COVID-19 vaccines, but proof of a direct, causal relationship is missing.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fmed.2023.1242225","type":"journal-article","created":{"date-parts":[[2023,9,22]],"date-time":"2023-09-22T06:12:35Z","timestamp":1695363155000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":6,"title":["Herpetic anterior uveitis following COVID-19 vaccines: a case series"],"prefix":"10.3389","volume":"10","author":[{"given":"Muriel","family":"Ott","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thanoosha","family":"Nagamany","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Souska","family":"Zandi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Pichi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aniruddha","family":"Agarwal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ester","family":"Carre\u00f1o","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vishali","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dilraj S.","family":"Grewal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmett T.","family":"Cunningham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marion R.","family":"Munk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,9,22]]},"reference":[{"key":"ref1","volume-title":"Director-General's opening remarks at the media briefing on COVID-19","year":"2020"},{"key":"ref2","volume-title":"Federal register","author":"Secretary","year":"2020"},{"key":"ref3","volume-title":"COVID-19: How EMA fast-tracks development support and approval of medicines and vaccines [press release]","year":"2020"},{"key":"ref4","volume-title":"UK medicines regulator gives approval for first UK COVID-19 vaccine","year":""},{"key":"ref5","doi-asserted-by":"publisher","first-page":"e122","DOI":"10.15190\/d.2021.1","article-title":"First COVID-19 vaccines receiving the US FDA and EMA emergency use authorization","volume":"9","author":"Fortner","year":"2021","journal-title":"Discoveries"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1001\/jama.2021.8565","article-title":"Effect of 2 inactivated SARS-CoV-2 vaccines on symptomatic COVID-19 infection in adults: a randomized clinical trial","volume":"326","author":"al Kaabi","year":"2021","journal-title":"JAMA"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"1703","DOI":"10.1016\/S1473-3099(22)00506-0","article-title":"Efficacy, safety, and immunogenicity of a booster regimen of Ad26.COV2.S vaccine against COVID-19 (ENSEMBLE2): results of a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"22","author":"Hardt","year":"2022","journal-title":"Lancet Infect Dis"},{"key":"ref8","first-page":"48","article-title":"Vaccine-associated uveitis","volume":"113","author":"Benage","year":"2016","journal-title":"Mo Med"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1097\/ICB.0b013e318193491b","article-title":"Bilateral panuveitis after influenza vaccination","volume":"3","author":"Wells","year":"2009","journal-title":"Retin Cases Brief Rep"},{"key":"ref10","first-page":"3838","article-title":"Two cases of exudative retina detachment and uveitis following H1N1 influenza vaccination","volume":"124","author":"Tao","year":"2011","journal-title":"Chin Med J"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"26","DOI":"10.3109\/15569520903427717","article-title":"Hepatitis B vaccine and uveitis: an emerging hypothesis suggested by review of 32 case reports","volume":"29","author":"Fraunfelder","year":"2010","journal-title":"Cutan Ocul Toxicol"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"65","DOI":"10.2174\/15748863113086660062","article-title":"Human papilloma virus vaccine associated uveitis","volume":"9","author":"Holt","year":"2014","journal-title":"Curr Drug Saf"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1016\/S0140-6736(87)93027-3","article-title":"Uveitis after hepatitis B vaccination","volume":"2","author":"Fried","year":"1987","journal-title":"Lancet"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1016\/j.ophtha.2022.08.027","article-title":"Vaccine-associated uveitis after COVID-19 vaccination: vaccine adverse event reporting system database analysis","volume":"130","author":"Singh","year":"2022","journal-title":"Ophthalmology"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1186\/s12348-021-00275-x","article-title":"Ocular inflammatory events following COVID-19 vaccination: a multinational case series","volume":"12","author":"Testi","year":"2022","journal-title":"J Ophthalmic Inflamm Infect"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.1001\/jamaophthalmol.2021.3477","article-title":"Association of ocular adverse events with inactivated COVID-19 vaccination in patients in Abu Dhabi","volume":"139","author":"Pichi","year":"2021","journal-title":"JAMA Ophthalmol"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.jdcr.2021.04.014","article-title":"Varicella-zoster virus reactivation after SARS-CoV-2 BNT162b2 mRNA vaccination: report of 5 cases","volume":"12","author":"Rodriguez-Jimenez","year":"2021","journal-title":"JAAD Case Rep"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"e6","DOI":"10.1111\/jdv.17646","article-title":"Varicella-zoster and herpes simplex virus reactivation post-COVID-19 vaccination: a review of 40 cases in an international dermatology registry","volume":"36","author":"Fathy","year":"2022","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"SI90","DOI":"10.1093\/rheumatology\/keab345","article-title":"Herpes zoster following BNT162b2 mRNA COVID-19 vaccination in patients with autoimmune inflammatory rheumatic diseases: a case series","volume":"60","author":"Furer","year":"2021","journal-title":"Rheumatology"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"e04883","DOI":"10.1002\/ccr3.4883","article-title":"Herpes-like skin lesion after AstraZeneca vaccination for COVID-19: a case report","volume":"9","author":"Ardalan","year":"2021","journal-title":"Clin Case Rep"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"e05188","DOI":"10.1002\/ccr3.5188","article-title":"Reactivation of herpes zoster after vaccination with an inactivated vaccine: a case report from Nepal","volume":"9","author":"Shah","year":"2021","journal-title":"Clin Case Rep"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"3529","DOI":"10.1111\/bcp.15280","article-title":"Association study between herpes zoster reporting and mRNA COVID-19 vaccines (BNT162b2 and mRNA-1273)","volume":"88","author":"Preta","year":"2022","journal-title":"Br J Clin Pharmacol"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"1078","DOI":"10.1056\/NEJMoa2110475","article-title":"Safety of the BNT162b2 mRNA Covid-19 vaccine in a Nationwide setting","volume":"385","author":"Barda","year":"2021","journal-title":"N Engl J Med"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1038\/clpt.1981.154","article-title":"A method for estimating the probability of adverse drug reactions","volume":"30","author":"Naranjo","year":"1981","journal-title":"Clin Pharmacol Ther"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1016\/S0140-6736(99)00623-6","article-title":"Reactivation of herpesvirus infections after vaccinations?","volume":"353","author":"Walter","year":"1999","journal-title":"Lancet"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"e13055","DOI":"10.1111\/irv.13055","article-title":"Influenza vaccine and subsequent development of zoster","volume":"17","author":"Wei","year":"2023","journal-title":"Influenza Other Respir Viruses"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1080\/21645515.2016.1235105","article-title":"HSV2 reactivation and myelitis following influenza vaccination","volume":"13","author":"Lieberman","year":"2017","journal-title":"Hum Vaccin Immunother"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.jaad.2021.03.092","article-title":"Cutaneous reactions reported after Moderna and Pfizer COVID-19 vaccination: a registry-based study of 414 cases","volume":"85","author":"McMahon","year":"2021","journal-title":"J Am Acad Dermatol"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1111\/bjd.20639","article-title":"Cutaneous reactions after SARS-CoV-2 vaccination: a cross-sectional Spanish nationwide study of 405 cases","volume":"186","author":"Catala","year":"2022","journal-title":"Br J Dermatol"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"784145","DOI":"10.3389\/fimmu.2021.784145","article-title":"Case report: cytomegalovirus reactivation and pericarditis following ChAdOx1 nCoV-19 vaccination against SARS-CoV-2","volume":"12","author":"Pluss","year":"2021","journal-title":"Front Immunol"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"1417","DOI":"10.3390\/vaccines10091417","article-title":"Cytomegalovirus Proctitis developed after COVID-19 vaccine: a case report and literature review","volume":"10","author":"Lv","year":"2022","journal-title":"Vaccines"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"e1344","DOI":"10.1097\/TXD.0000000000001344","article-title":"CMV infection following mRNA SARS-CoV-2 vaccination in solid organ transplant recipients","volume":"8","author":"Chakravorty","year":"2022","journal-title":"Transplant Direct"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1080\/09273948.2017.1420806","article-title":"Clinical characteristics of herpes simplex virus associated anterior uveitis","volume":"26","author":"Wensing","year":"2018","journal-title":"Ocul Immunol Inflamm"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"14","DOI":"10.5301\/ejo.5000331","article-title":"Presumed herpetic anterior uveitis: a study with retrospective analysis of 79 cases","volume":"24","author":"Nalcacioglu-Yuksekkaya","year":"2014","journal-title":"Eur J Ophthalmol"},{"key":"ref35","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.2147\/OPTH.S60394","article-title":"Current aspects on the management of viral uveitis in immunocompetent individuals","volume":"9","author":"Pleyer","year":"2015","journal-title":"Clin Ophthalmol"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"356","DOI":"10.4103\/sjopt.sjopt_80_22","article-title":"Viral anterior uveitis","volume":"36","author":"Gozzi","year":"2022","journal-title":"Saudi J Ophthalmol"},{"key":"ref37","doi-asserted-by":"publisher","first-page":"3350","DOI":"10.1111\/jocd.14521","article-title":"Can SARS-CoV-2 vaccine increase the risk of reactivation of varicella zoster? A systematic review","volume":"20","author":"Desai","year":"2021","journal-title":"J Cosmet Dermatol"},{"key":"ref38","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1056\/NEJMoa2035389","article-title":"Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine","volume":"384","author":"Baden","year":"2021","journal-title":"N Engl J Med"},{"key":"ref39","doi-asserted-by":"publisher","first-page":"2603","DOI":"10.1056\/NEJMoa2034577","article-title":"Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine","volume":"383","author":"Polack","year":"2020","journal-title":"N Engl J Med"},{"key":"ref40","doi-asserted-by":"publisher","first-page":"1390","DOI":"10.1001\/jama.2021.15072","article-title":"Surveillance for adverse events after COVID-19 mRNA vaccination","volume":"326","author":"Klein","year":"2021","journal-title":"JAMA"},{"key":"ref41","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/j.ajo.2022.02.011","article-title":"COVID-19 vaccination and the eye","volume":"240","author":"Wang","year":"2022","journal-title":"Am J Ophthalmol"},{"key":"ref42","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1007\/s40123-021-00415-5","article-title":"The eye of the storm: COVID-19 vaccination and the eye","volume":"11","author":"Ng","year":"2022","journal-title":"Ophthalmol Ther"},{"key":"ref43","doi-asserted-by":"publisher","first-page":"941","DOI":"10.3390\/vaccines10060941","article-title":"Ocular complications after COVID-19 vaccination, vaccine adverse event reporting system","volume":"10","author":"Nyankerh","year":"2022","journal-title":"Vaccines"},{"key":"ref44","doi-asserted-by":"publisher","first-page":"e20967","DOI":"10.7759\/cureus.20967","article-title":"Herpetic keratitis and corneal Endothelitis following COVID-19 vaccination: a case series","volume":"14","author":"Alkwikbi","year":"2022","journal-title":"Cureus"},{"key":"ref45","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1186\/s13256-022-03350-6","article-title":"Herpetic anterior uveitis following Pfizer-BioNTech coronavirus disease 2019 vaccine: two case reports","volume":"16","author":"Ortiz-Egea","year":"2022","journal-title":"J Med Case Rep"},{"key":"ref46","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1080\/09273948.2019.1626188","article-title":"Vaccine-associated uveitis","volume":"27","author":"Cunningham","year":"2019","journal-title":"Ocul Immunol Inflamm"},{"key":"ref47","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1038\/s41577-021-00526-x","article-title":"COVID-19 vaccines: modes of immune activation and future challenges","volume":"21","author":"Teijaro","year":"2021","journal-title":"Nat Rev Immunol"}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2023.1242225\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,22]],"date-time":"2023-09-22T06:12:40Z","timestamp":1695363160000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2023.1242225\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,22]]},"references-count":47,"alternative-id":["10.3389\/fmed.2023.1242225"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2023.1242225","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,9,22]]},"article-number":"1242225"}}